Publicação científica trimestral do CREMERJ - número 3 - 2022

34 Miocardite aguda: 16 pontos que todo médico deve conhecer Evandro Tinoco Mesquita et al. Med. Ciên. e Arte , Rio de Janeiro, v.1, n.3, p.21-35, jul-set 2022 REFERÊNCIAS 1. Kociol RD, Cooper LT, Fang JC, Moslehi FL, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement from the American Heart Association. Circulation 2020, 141, E69-E92. [CrossRef] [PubMed]. 2. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliõ T, Heymans S, Jahns R, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013, 34, 2636-2648. [CrossRef] [PubMed]. 3. Law YM, Lal AK, Chen S, iháková D, Cooper LT Jr., Deshpande S, Godown J, Grosse-Wortmann L, Robinson JD, Towbin JA. Diagnosis and Management of Myocarditis in Children: A Scientific Statement from the American Heart Association. Circulation 2021, /44, e123-e135. [CrossRef] [PubMed]. 4. Caforio ALP, Malipiero G, Marcolongo R, Iliceto S. Myocarditis: A Clinicai Overview. Curr Cardiol Rep. 2017, 19, 63. [CrossRef] [PubMed]. 5. Tschõpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hübner N, et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat Rev Cardiol. 2021, /8, 169-193. [CrossRef]. 6. Montera, Marcelo Westerlund et al. Diretriz de Miocardites da Sociedade Brasileira de Cardiologia–2022. Arquivos Brasileiros de Cardiologia, v. 119, p. 143-211, 2022. 7. Pomiato, Elettra et al. Pediatric Myocarditis: What Have We Learnt So Far?. Journal of Cardiovascular Development and Disease, v. 9, n. 5, p. 143, 2022. 8. Ryan TD, Nagarajan R, Godown J. Cardiovascular toxicities in pediatric cancer survivors. Cardiol Clin. 2019;37(4):533-44. doi: 10.1016/j. ccl.2019.07.002. 9. Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, GregoryW, et al. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. oncologist. 2018;23(8):874-78. doi: 10.1634/theoncologist.2018-0157. 10. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80-91. doi: 10.1161/CIRCULATIONAHA.118.034497. 11. Law, Yuk M, et al. Diagnosis and management of myocarditis in children: a scientific statement from the American Heart Association. Circulation, v. 144, n. 6, p. e123-e135, 2021. 12. Pillay, Jennifer et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ, v. 378, 2022. 13. Torbey AFM, Grippa de Souza ALAA, Bustamante ACD, Brandão ACZ, Abdallah LR, March e Souza YPD, Mesquita ET. Acute Myocarditis in Childhood and Adolescence in the Covid-19 Era. ABC Heart Fail Cardiomyop. 2021; 1(1):44-54. doi: https://doi.org/10.36660/abchf.20210008 14. Bajaj R, Sinclair HC, Patel K, Low B, Pericao A, Manisty C, et al. Delayed-onset myocarditis following COVID-19. Lancet Respir Med. 2021;9(4):e32-e34. doi: 10.1016/S2213-2600(21)00085-0. ao projeto RENOMICA (Rede Nacional de Genética Cardíaca), em nome da Profª Dra. Adriana Carvalho, do Instituto Nacional de Cardiologia - INC e do Ministério da Saúde que em parceria com o grupo de registro das miocardites ChARisMa tem trabalhado com Medicina de Precisão acessível a todos os pacientes do SUS.